H-CYTE, Inc. (OTCMKTS:HCYTD – Get Free Report)’s stock price was down 49.5% during mid-day trading on Wednesday . The stock traded as low as $2.02 and last traded at $2.02. Approximately 400 shares traded hands during mid-day trading, an increase of 288% from the average daily volume of 103 shares. The stock had previously closed at $4.00.
H-CYTE Stock Performance
The business has a 50 day moving average of $2.02 and a 200 day moving average of $2.02.
About H-CYTE
H-CYTE, Inc, a biopharmaceutical company, develops and delivers various treatments for patients with chronic respiratory and pulmonary disorders in the United States. The company develops and implements treatment options in autologous cellular therapy to treat chronic lung disorders. It has a product supply agreement with Rion, LLC to develop and distribute a biologic for chronic obstructive pulmonary disease.
See Also
- Five stocks we like better than H-CYTE
- Upcoming IPO Stock Lockup Period, Explained
- Hedge Funds Boost Oil Positions: Is a Major Rally on the Horizon?
- What Do S&P 500 Stocks Tell Investors About the Market?
- Power Play: Japan’s Top Auto Stocks Eye Historic Merger
- Expert Stock Trading Psychology Tips
- S&P 500 Earnings Set to Shine: January’s Critical Market Test
Receive News & Ratings for H-CYTE Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for H-CYTE and related companies with MarketBeat.com's FREE daily email newsletter.
